 |
 |
 |
|
 |
articles < press << main |
 |
 |
|
|
|
|
|
|
|
| date | | | | title / topic / summary | sort by topic |
|---|
|
| 06/08/2005 | | | | Nymox Reports Positive New Data for BPH Drug
topic: R&D: BPH (enlarged prostate) Treatments
June 8, 2005: Nymox announced
today new longer term follow-up results from Phase 1-2 testing of NX-1207, the Company's
investigational new drug for benign prostatic hyperplasia (BPH). The trial data indicated
that at 18-23 months' follow-up, there was symptomatic improvement and no safety issues in
individuals treated with NX-1207. |
| 05/26/2005 | | | | Newly Published Studies Show Danger of Second Hand Smoke
topic: Tobacco Exposure Tests
May 26, 2005: The evidence continues to mount about the bad health effects
caused by second-hand smoke. According to a special report published in the latest issue
of Circulation, the journal of the American Heart Association, the impact of
second-hand smoke exposure on the heart and circulatory system is substantial and rapid
and nearly as large as actual smoking. |
| 05/25/2005 | | | | FDA Advisory Panel Meeting for Nymox PMA Application Expected in July 2005
topic: AlzheimAlert™ & Diagnosis of Alzheimer's Disease
May 25, 2005: Nymox Pharmaceutical Corporation announced today that it has been informed that the Company's Premarket Approval (PMA)
application to FDA concerning a kit version of the Company's AlzheimAlert™ urine test
will be going forward to a presentation before a panel of the Medical Devices Advisory
Committee which is expected in July of this year. |
| 05/18/2005 | | | | Nymox and InnerLink Sign Agreement to Promote Nymox Tobacco Exposure Products
topic: Tobacco Exposure Tests
May 18, 2005: Nymox announced
today the signing of an agreement with InnerLink, Inc. to promote the marketing, use and
sales of TobacAlert™ and NicAlert™, the Company's proprietary tests for tobacco
exposure. InnerLink is a leader in health and safety education with a specific emphasis on
community-based tobacco control programs. |
| 05/17/2005 | | | | Another Large New Published Study Shows that Taking a Statin Drug Reduces the Risk of Dementia
topic: Statins and Alzheimer's Disease
May 17, 2005: Taking a statin drug reduces the risk of all types of
dementia, including Alzheimer's disease, by 44% according to a large study of 8,574
patients published in the current issue of Neurology. Nymox holds U.S. and global patent rights for the use of statin drugs for the
prevention and treatment of Alzheimer's disease, the leading cause of dementia in the
elderly. |
| 05/13/2005 | | | | Nymox Reports First Quarter 2005 Financial Results
topic: Financial
May 13, 2005: Nymox Pharmaceutical Corporation announced today its financial results for the first quarter of 2005. |
| 05/12/2005 | | | | Standard & Poor's Stock Reports Gives Nymox “Bullish” Rating
topic: Financial
May 12, 2005: Nymox Pharmaceutical Corporation received
favorable coverage in a new Standard & Poor's Stock Report. The new report on Nymox
rates the stock as “bullish” on technical evaluation. |
| 05/11/2005 | | | | New Study Finds Evidence that Taking a Statin Drug Can Help Treat Alzheimer's Disease
topic: Statins and Alzheimer's Disease
May 11, 2005: According to a newly published study, a daily dose of atorvastatin
(Lipitor®) could help slow the progressive deterioration of mental function and behavior
usually found in mild to moderate Alzheimer's disease patients. Nymox holds U.S. and global patent rights for
the use of statin drugs for the prevention and treatment of Alzheimer's disease. |
| 05/10/2005 | | | | Statin Drugs Offer Positive New Pharmaceutical Approach to Alzheimer's Disease Treatment and Prevention
topic: Statins and Alzheimer's Disease
May 10, 2005: Statins provide Nymox Pharmaceutical Corporation
with a new approach to the treatment and prevention of Alzheimer's disease. Statins are a class of cholesterol-lowering drugs that are the biggest-selling
prescription pills in pharmaceutical history with estimated 2004 global sales of up to $26
billion. |
| 05/06/2005 | | | | Second-Hand Smoke Exposure a Key Topic at National Conference on Tobacco or Health
topic: Tobacco Exposure Tests
May 6, 2005: The interest in Nymox's tobacco exposure products at the 2005 National Conference on Tobacco or Health “tremendous” according to Brian Doyle, the Company's Global Sales
Manager. More than 2,800
doctors, nurses, researchers, lawmakers and tobacco control activists from across the U.S. attended the conference. |
|